Researchers developed ErythroMer, artificial red blood cells designed to emulate vital functions of natural cells and be freeze-dried for ambient-temperature storage. If safe for humans, they could offer an alternative to transfusions where donated blood is difficult to obtain or store.
KaloCyte co-founders and scientists, with collaborators on the CONCERT team funded by DARPA FSHARP, developed L-TOF to compare oxygen delivery potency across blood products and predict transfusion quality.
ErythroMer, a nanotechnology-based artificial red blood cell product, emulated normal red blood cell interactions with oxygen and nitric oxide, according to results of a proof-of-concept study presented at the ASH Annual Meeting and Exposition.
Elaine Haynes is the President and Chief Executive Officer of KaloCyte, where she oversees the company’s business operations and drives execution on ErythroMer’s technical development and grant funding strategies.
KaloCyte is developing ErythroMer, a dried, bio-inspired artificial red blood cell, to treat life-threatening blood loss when stored red blood cells are unavailable, undesirable or in short supply.
